ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)

Completed · Not applicable

Conditions studied: Aortic Stenosis, Mitral Stenosis, Aortic Valve Insufficiency, Mitral Valve Insufficiency, Heart Failure

In brief

The objective of this trial is to confirm that the modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.

Key facts

Study ID: NCT01757665
Run by: Edwards Lifesciences
People needed: 777
Starts: 2012-12-11
Expected to finish: 2026-03-23
Last updated by the study team: 2026-05-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Is 18 years or older
Provides written informed consent prior to trial procedures
Agrees to attend all follow-up assessments for up to 5 years and is willing to comply with specified follow-up evaluations at clinical investigational sites that are participating in the COMMENCE trial and/or obtain the protocol-specified diagnostic tests at centers that are under the same IRB or the same healthcare system
Diagnosed with aortic or mitral valve disease requiring valve replacement based on pre- operative evaluation
Scheduled to undergo planned aortic or mitral valve replacement with or without concomitant bypass surgery
Scheduled to undergo planned aortic valve replacement with or without resection and replacement of the ascending aorta from the sinotubular junction and without the need for circulatory arrest for hemi arch or arch replacement

You may not qualify if…

A subject meeting any of the following criteria shall be excluded:
Requires emergency surgery
Requires planned multiple valve replacement/ repair (with the exception of mitral valve replacement with tricuspid valve repair)
Has prior valve surgery, which included implant of a bioprosthetic valve, mechanical valve, or annuloplasty ring that will remain in situ
Requires a surgical procedure outside of the cardiac area (e.g. vascular bypass)
Requires surgical replacement of the aortic root
Has active endocarditis/myocarditis or endocarditis/myocarditis within 3 months to the scheduled aortic or mitral valve replacement surgery
Has renal insufficiency as determined by creatinine (S-Cr) level ≥ 2.5 mg/dL or end -stage renal disease requiring chronic dialysis at screening visit
Has MRI or CT scan confirmed stroke, cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months (180 days) prior to planned valve surgery
Has acute myocardial infarction (MI) within 30 days prior to planned valve surgery
Has presence of non-cardiac disease limiting life expectancy to less than 12 months
Diagnosed with hypertrophic obstructive cardiomyopathy (HOCM)
Diagnosed with abnormal calcium metabolism and hyperparathyroidism
Exhibits left ventricular ejection fraction ≤ 20% as validated by diagnostic procedure prior to planned valve surgery
Echocardiographic evidence of an intra-cardiac mass, thrombus, or vegetation
Hemodynamic or respiratory instability requiring inotropic support, mechanical circulatory support, or mechanical ventilation within 30 days prior to planned valve surgery
Documented leukopenia (WBC < 3.5x 10³/μL), acute anemia (Hgb < 10.0 gm/dL or 6 mmol/L) or thrombocytopenia (platelet count < 50x 10³/μL) accompanied by history of bleeding diathesis and coagulopathy
Has prior organ transplant or is currently an organ transplant candidate
Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial
Was previously implanted with trial device (Model 11000A or Model 11000M)
Pregnant (female subject of childbearing potential only), lactating or planning to become pregnant during the duration of participation in trial
Currently incarcerated or unable to give voluntary informed consent
Documented history of substance (drug or alcohol) abuse within the last 5 years prior to implant
Requires concomitant left ventricular assist device (LVAD) placement

Where it is running

Cardiology, P.C. — Birmingham, Alabama, United States
University of Southern California — Los Angeles, California, United States
Sutter Institute for Medical Research — Sacramento, California, United States
Board of Trustees of the Leland Stanford Junior University — Stanford, California, United States
Yale-New Haven — New Haven, Connecticut, United States
Shands at the University of Florida — Gainesville, Florida, United States
Florida Hospital — Orlando, Florida, United States
Emory University Hospital Midtown — Atlanta, Georgia, United States
St. Vincent Heart Center of Indiana — Indianapolis, Indiana, United States
University of Kansas Medical Center — Kansas City, Kansas, United States
University of Maryland, Baltimore — Baltimore, Maryland, United States
Spectrum Health Hospital — Grand Rapids, Michigan, United States
North Mississippi Medical Center — Tupelo, Mississippi, United States
Missouri Baptist Medical Center — St Louis, Missouri, United States
Washington University/ Barnes Jewish Hospital — St Louis, Missouri, United States
New York Weill Cornell Medical Center — New York, New York, United States
Mount Sinai Morningside — New York, New York, United States
Icahn School of Medicine at Mount Sinai — New York, New York, United States
New York Presbyterian Hospital - Columbia University Medical Center — New York, New York, United States
Cleveland Clinic Foundation — Cleveland, Ohio, United States
OhioHealth Research Institute — Columbus, Ohio, United States
The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
Pinnacle Health Cardiovascular Institute — Mechanicsburg, Pennsylvania, United States
Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
St. Thomas Health — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.